A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A

Trial Profile

A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Aug 2017

At a glance

  • Drugs SB 525 (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Alta
  • Sponsors Sangamo Therapeutics
  • Most Recent Events

    • 25 Aug 2017 According to a Sangamo Therapeutics media release, first patient has been dosed.
    • 08 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 07 Jun 2017 According to a Sangamo Therapeutics media release, initial data from this study are expected in late 2017 or early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top